Skip to main
PEN

Penumbra (PEN) Stock Forecast & Price Target

Penumbra (PEN) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 20%
Buy 13%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Penumbra is a leading biomedical devices and services company, specializing in minimally invasive endovascular treatments for neurovascular and peripheral vascular disorders. The company has seen impressive growth in recent years, with preliminary Q4/25 revenue expected to be in the range of $383.0M-$384.8M (+21.4%-+22.0% Y/Y) and a strong operating margin of 14.8%-15.7%. While the recent acquisition by Boston Scientific (BSX) may lead to concerns about competition and potential antitrust issues, Penumbra's differentiated technology platform and continued innovation make it well-positioned to maintain and potentially increase its market share in the fast-evolving acute ischemic stroke treatment market.

Bears say

Penumbra is being acquired by Boston Scientific in a stock-and-cash transaction for $374 per share, which values the company at approximately $14.5 billion. While this acquisition has been the subject of speculation for some time, and Penumbra's flagship product has been gaining market share and has strong clinical evidence, there are potential risks from patent and product liability litigation, as well as the company's heavy reliance on new product introductions and competitive markets. Additionally, Boston Scientific itself faces challenges with patent litigation and product liability, as well as the potential for deterioration in its CRM and DES businesses and risks associated with numerous acquisitions.

Penumbra (PEN) has been analyzed by 15 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 13% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Penumbra (PEN) Forecast

Analysts have given Penumbra (PEN) a Hold based on their latest research and market trends.

According to 15 analysts, Penumbra (PEN) has a Hold consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $362, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $362, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Penumbra (PEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.